Nintedanib Centrafarm

Nintedanib, the active ingredient in Nintedanib Centrafarm, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain forms of non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Centrafarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution across multiple regulatory jurisdictions.

Nintedanib is used in fibrotic lung diseases and selected oncology indications, where inhibition of multiple growth factor receptors slows disease progression.

- Idiopathic pulmonary fibrosis: reduces decline in lung function and delays disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and stabilises respiratory symptoms. - Non‑small cell lung cancer (specific histology): used in combination therapy to inhibit tumor angiogenesis and growth.

Nintedanib may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Diarrhoea: frequent, may be mild to moderate. - Nausea: occasional, often transient. - Elevated liver enzymes (ALT/AST): observed in routine monitoring. - Decreased appetite: may affect nutritional intake.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring discontinuation. - Cardiovascular events: arterial thromboembolism or myocardial infarction. - Severe bleeding: gastrointestinal or intracranial haemorrhage.

Before initiating Nintedanib, clinicians should evaluate several safety considerations to minimise risk.

- Liver function: assess baseline transaminases and monitor regularly. - Bleeding risk: avoid in patients with active bleeding or on anticoagulants without careful assessment. - Gastrointestinal health: monitor for severe diarrhoea and dehydration. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with obstetric specialist. - Store below 25°C: keep in original container, protect from moisture and light.

Concomitant medicines can alter Nintedanib exposure or increase toxicity; interactions are grouped by clinical relevance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels, increasing adverse events. - Anticoagulants (warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - P‑glycoprotein inhibitors (e.g., verapamil): modest increase in exposure. - NSAIDs or antiplatelet agents: additive bleeding potential. - St. John’s wort: may lower drug concentrations.